[{"id":"fcac23dd-b9f8-4aaf-8d6b-1909796654a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06120036","created_at":"2023-11-07T16:14:23.232Z","updated_at":"2025-02-25T13:41:53.523Z","phase":"Phase 1","brief_title":"Dosing and Tolerability of Deoxycholic Acid Vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas","source_id_and_acronym":"NCT06120036","lead_sponsor":"Massachusetts General Hospital","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/06/2022","start_date":" 12/06/2022","primary_txt":" Primary completion: 01/09/2025","primary_completion_date":" 01/09/2025","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-21"},{"id":"10adfe7c-1a6c-43eb-9d18-a1d7306c999a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04166383","created_at":"2021-01-18T20:19:48.675Z","updated_at":"2024-07-02T16:35:29.876Z","phase":"Phase 2","brief_title":"VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT04166383","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ofranergene obadenovec (VB-111)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 08/09/2020","start_date":" 08/09/2020","primary_txt":" Primary completion: 04/12/2022","primary_completion_date":" 04/12/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-11-08"},{"id":"cc90b421-9392-40ee-ba43-05c6880719cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206073","created_at":"2021-01-18T15:48:11.018Z","updated_at":"2024-07-02T16:35:32.012Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer","source_id_and_acronym":"NCT03206073","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Imjudo (tremelimumab-actl) • Pexa-Vec (pexastimogene devacirepvec)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 12/07/2017","start_date":" 12/07/2017","primary_txt":" Primary completion: 09/24/2020","primary_completion_date":" 09/24/2020","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2023-10-24"},{"id":"f3c142f1-ba9c-4254-9603-796c3a4ecc92","acronym":"","url":"https://clinicaltrials.gov/study/NCT01397929","created_at":"2021-01-18T05:44:35.065Z","updated_at":"2025-02-25T13:33:52.144Z","phase":"Phase 1/2","brief_title":"An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors","source_id_and_acronym":"NCT01397929","lead_sponsor":"Basilea Pharmaceutica","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lisavanbulin (BAL101553)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2023-05-10"},{"id":"7d68e07b-11ee-4609-9459-b4a8e162aed2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454165","created_at":"2021-01-18T17:01:54.498Z","updated_at":"2024-07-02T16:35:58.227Z","phase":"Phase 1","brief_title":"A Study of BNC105P Combined With Ibrutinib","source_id_and_acronym":"NCT03454165","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" BCL2 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression","tags":["BCL2 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • BNC105"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 01/14/2021","primary_completion_date":" 01/14/2021","study_txt":" Completion: 01/14/2021","study_completion_date":" 01/14/2021","last_update_posted":"2023-01-04"},{"id":"5363ddba-ce3b-4487-8a21-7cccbee4cdbe","acronym":"INTRANS","url":"https://clinicaltrials.gov/study/NCT03754140","created_at":"2021-06-15T21:52:36.260Z","updated_at":"2024-07-02T16:36:07.298Z","phase":"Phase 2","brief_title":"Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases","source_id_and_acronym":"NCT03754140 - INTRANS","lead_sponsor":"Melanoma Institute Australia","biomarkers":" CD20 • CD8 • CD163 • CD4 • NCAM1 • CD68 • CD31 • FOXP3 • PECAM1","pipe":"","alterations":" ","tags":["CD20 • CD8 • CD163 • CD4 • NCAM1 • CD68 • CD31 • FOXP3 • PECAM1"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/20/2020","start_date":" 05/20/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-07-14"},{"id":"11179753-861b-4698-95e1-75dc7ec8aaaa","acronym":"METROmaJX","url":"https://clinicaltrials.gov/study/NCT02630368","created_at":"2021-01-18T12:47:25.773Z","updated_at":"2025-02-25T16:15:31.717Z","phase":"Phase 1/2","brief_title":"A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)","source_id_and_acronym":"NCT02630368 - METROmaJX","lead_sponsor":"Institut Bergonié","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • cyclophosphamide • Pexa-Vec (pexastimogene devacirepvec) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 197","initiation":"Initiation: 09/18/2015","start_date":" 09/18/2015","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2022-02-02"},{"id":"ff707ef8-060e-474b-a559-9dbdfbdf688b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01394939","created_at":"2021-01-18T05:43:45.759Z","updated_at":"2024-07-02T16:36:36.446Z","phase":"Phase 1/2","brief_title":"Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma","source_id_and_acronym":"NCT01394939","lead_sponsor":"Jennerex Biotherapeutics","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Pexa-Vec (pexastimogene devacirepvec)"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2021-01-08"},{"id":"62baa3b1-251d-4248-8d27-8479e939d9d7","acronym":"PHOCUS","url":"https://clinicaltrials.gov/study/NCT02562755","created_at":"2021-07-05T16:46:12.243Z","updated_at":"2024-07-02T16:36:37.324Z","phase":"Phase 3","brief_title":"Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone","source_id_and_acronym":"NCT02562755 - PHOCUS","lead_sponsor":"SillaJen, Inc.","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Pexa-Vec (pexastimogene devacirepvec)"],"overall_status":"Completed","enrollment":" Enrollment 459","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2020-12-16"},{"id":"c72fcab2-47e2-44ff-b31e-46bbe6c6905c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01305213","created_at":"2021-01-18T05:18:32.660Z","updated_at":"2024-07-02T16:36:57.567Z","phase":"Phase 2","brief_title":"Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer","source_id_and_acronym":"NCT01305213","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • Zybrestat (fosbretabulin)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 03/21/2011","start_date":" 03/21/2011","primary_txt":" Primary completion: 08/20/2016","primary_completion_date":" 08/20/2016","study_txt":" Completion: 11/03/2016","study_completion_date":" 11/03/2016","last_update_posted":"2019-07-30"},{"id":"37e7ef56-b650-4b32-a176-09f449bac0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02132468","created_at":"2021-01-18T09:53:32.107Z","updated_at":"2024-07-02T16:37:15.827Z","phase":"Phase 2","brief_title":"A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers","source_id_and_acronym":"NCT02132468","lead_sponsor":"Mateon Therapeutics","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zybrestat (fosbretabulin)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2017-12-05"},{"id":"dba0e6e2-594f-4f87-9d25-36bb519247e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01240590","created_at":"2021-01-18T04:59:45.037Z","updated_at":"2024-07-02T16:37:23.615Z","phase":"Phase 1/2","brief_title":"A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)","source_id_and_acronym":"NCT01240590","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • crolibulin (EPC2407)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 01/26/2011","start_date":" 01/26/2011","primary_txt":" Primary completion: 08/31/2015","primary_completion_date":" 08/31/2015","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2017-04-10"}]